Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

NCT05636111 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Paclitaxel
DRUG: Bevacizumab
DRUG: Lurbinectedin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]